KYTXKyverna Therapeutics, Inc.
Is it safe?
Caution warranted: heavy debt (BB) and big price swings.
Net cash, but unprofitable, speculative. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -94% · now 45% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can KYTX take a bad year?
Kyverna Therapeutics, Inc. holds $175M more cash than debt, so a bad year is a question about profits, not about lenders.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
- Annualised volatility
- 96%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $25M
- Cash and short-term investments
- $199M
- Net cash
- $175M
- EBITDA, trailing twelve months
- −$158M
- Operating profit, trailing twelve months
- −$159M
- Debt / equity
- 0.15×
- Annualised volatilitytwo years of daily moves
- 96%
- Worst drawdown on file
- −94%
- Below its 52-week high
- 45%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry